GAMMA Investing LLC Buys 240 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

GAMMA Investing LLC grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 46.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 758 shares of the biopharmaceutical company’s stock after buying an additional 240 shares during the period. GAMMA Investing LLC’s holdings in Intra-Cellular Therapies were worth $63,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ITCI. True Wealth Design LLC purchased a new stake in Intra-Cellular Therapies in the 3rd quarter worth approximately $32,000. Capital Performance Advisors LLP bought a new stake in shares of Intra-Cellular Therapies during the 3rd quarter valued at about $74,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Intra-Cellular Therapies during the third quarter worth about $97,000. Quarry LP increased its position in shares of Intra-Cellular Therapies by 260.0% in the third quarter. Quarry LP now owns 1,800 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 1,300 shares during the last quarter. Finally, Covestor Ltd lifted its holdings in shares of Intra-Cellular Therapies by 40.4% during the 3rd quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 521 shares during the last quarter. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Trading Up 14.9 %

NASDAQ:ITCI opened at $94.87 on Monday. The company has a market cap of $10.06 billion, a PE ratio of -109.04 and a beta of 0.70. Intra-Cellular Therapies, Inc. has a 12 month low of $62.78 and a 12 month high of $98.40. The company has a 50 day simple moving average of $85.57 and a two-hundred day simple moving average of $78.87.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $175.40 million during the quarter, compared to analysts’ expectations of $172.30 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.25) earnings per share. Research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on ITCI shares. JPMorgan Chase & Co. increased their price target on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. Morgan Stanley boosted their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Royal Bank of Canada boosted their price objective on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $97.23.

Insider Buying and Selling

In other news, CEO Sharon Mates sold 51,000 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Michael Halstead sold 22,869 shares of Intra-Cellular Therapies stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by insiders.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.